Summit Stock Falls on FDA Rejection for Lung Cancer Drug
Summit Therapeutics (SMMT) shares fell 20% after the FDA rejected its lung cancer drug, ivonescimab, due to insufficient evidence of effectiveness. The drug showed progression-free survival benefits but failed to meet overall survival endpoints. The setback delays U.S. launch plans and creates regulatory uncertainty. Year-to-date, SMMT shares are down 19.1%.
How this was made

The 30-second read
Why it matters
The FDA’s CRL delays potential U.S. launch and creates uncertainty around the resubmission pathway, directly affecting near-term revenue expectations and probability-weighted valuation.
Market read
A same-day FDA CRL with a cited effectiveness-evidence deficiency is a high-impact regulatory catalyst for the issuer, driving an immediate pre-market selloff.
What to watch
The article highlights PFS success and a favorable OS trend from longer-term follow-up, which may support a faster resubmission strategy if the FDA accepts the additional evidence package.
Background
Summit’s ivonescimab plus platinum chemotherapy BLA for NSCLC was supported by the Phase 3 HARMONi study, which showed PFS benefit but not statistically significant OS in the pivotal analysis.
Ticker impact
Summit Therapeutics received an FDA complete response letter for its ivonescimab BLA, citing insufficient evidence of effectiveness.
Likely further downside or elevated volatility as investors price in delayed resubmission and additional data needs.
The article states the FDA declined approval in the current form due to insufficient effectiveness evidence, and shares fell about 20% pre-market.
Market effects
Reinforces FDA scrutiny on overall survival evidence in oncology combo trials, potentially raising perceived regulatory bar for similar programs.
Primarily impacts U.S. biotech sentiment and risk appetite for oncology development names.
Limited direct global spillover beyond broader oncology regulatory expectations.
Counterpoint
A CRL is not a final rejection; if Summit can address the OS evidence gap with additional analyses or studies, the program could still regain approval odds.
Key entities
- companySummit Therapeutics
Subject of the article, issued an FDA complete response letter for its ivonescimab BLA.
- regulatorFDA
Issued the CRL, declining approval due to insufficient evidence of effectiveness.
- drug_candidateivonescimab
Biologic therapy whose BLA approval was rejected in its current form.
- clinical_trialHARMONi study
Phase 3 trial supporting the BLA, with PFS benefit but no statistically significant OS benefit in the pivotal endpoint.




